Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$4.16M-$4.16Mderivedno prior Q4 2022 on file EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$3,901,000— The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Incomederived-$4,163,233— Operating Cash Flowderived$5,606— ended Jan 31, 2023 · filed Dec 1, 2025 · 1035 d after period end